Usefulness of Once-Weekly GLP-1 Receptor Agonist Semaglutide on Glycemic Control in Subjects with Type 2 Diabetes Mellitus: Switching from the Same Class Dulaglutide in a Retrospective Observation Study

Table 3

Time course of various clinical parameters after switching from dulaglutide to semaglutide. (a) Study 1. (b) Study 2.

(a)

Parameter	-3 months	Baseline	3 months	6 months
BMI (kg/m^2)
HbA1c (%)
PG (mg/dL)
TG (mg/dL)
HDL-C (mg/dL)
LDL-C (mg/dL)
γ-GTP (U/L)
ALT (U/L)
AST (U/L)
Cre (mg/dL)
BUN (mg/dL)
eGFR (mL/min/1.73m^2)

(b)

Parameter	Dula continuation				Switching
	-3 months	Baseline	3 months	6 months	-3 months	Baseline	3 months	6 months
BMI (kg/m^2)
HbA1c (%)
PG (mg/dL)
TG (mg/dL)
HDL-C (mg/dL)
LDL-C (mg/dL)
γ-GTP (U/L)
ALT (U/L)
AST (U/L)
Cre (mg/dL)
BUN (mg/dL)
eGFR (mL/min/1.73m^2)

Abbreviations: BMI: body mass index; PG: plasma glucose; TG: triglyceride; HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol; γ-GTP: γ-glutamyl transpeptidase; ALT: alanine aminotransferase; AST: aspartate aminotransferase; Cre: creatinine; BUN: blood urea nitrogen; eGFR: estimated glomerular filtration rate. Data are shown as . vs. baseline.